Monitor the shareholder vote outcome and any subsequent pricing of the authorized share issuances; the massive potential dilution and worsening financials create significant downside risk for existing holders.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 2 $0.1083entry
- T+1 · 14d ago +1.39%α +1.09% · $0.1098
- T+5 · 8d ago −11.54%α −11.62% · $0.0958
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vivos Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on November 2, 2026, four days after its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting. The filing does not contain new substantive text beyond the cover page and graphic images; the proxy statement itself seeks shareholder approval on 10 proposals including a reverse stock split, massive potential share issuances to two investors, an equity plan increase, and a reincorporation from Delaware to Nevada. The company has a $4M market cap, widening net losses ($21.2M in 2025 vs $11.1M in 2024), and substantial dilution risk from existing convertible securities.
Key Facts
- DEFA14A filed on 2026-11-02, supplementing the DEF 14A filed 2026-10-29 for the 2026 Annual Meeting
- 10 proposals include reverse stock split (1-for-20 to 1-for-40), potential issuance of up to 18.5M shares to New Seneca Partners and up to 80M shares to SOD Sciences, 4.9M share increase to equity plan, and reincorporation from Delaware to Nevada
- Market cap is $4M; net loss widened to $21.2M in 2025 from $11.1M in 2024
- CEO compensation actually paid was negative per the proxy statement
- Substantial dilution risk from existing convertible securities
Financial Impact
Potential dilution from up to 98.5M new shares (18.5M to New Seneca Partners + 80M to SOD Sciences) against a $4M market cap; net loss of $21.2M in 2025
Risk Factors
- Massive dilution from authorized share issuances to New Seneca Partners and SOD Sciences
- Widening net losses and negative CEO compensation indicate financial distress
- Reverse stock split needed to regain Nasdaq bid-price compliance, signaling potential delisting risk
- Reincorporation to Nevada may reduce shareholder protections
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-049503 |
| Document: 0001493152-26-049503-index-headers.html | 0001493152-26-049503 |
| Document: 0001493152-26-049503-index.html | 0001493152-26-049503 |
| Document: 0001493152-26-049503.txt | 0001493152-26-049503 |
Track record
22 reports on VVOS
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +80.62% at T+60 after the Jun 8, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $0.0852 Now $0.0820 +3.76% settles Feb 16
- Nov 2, 202614d ago DEFA14A Bearish 6/10 Viewing Entry $0.1083 Now $0.0820 +24.28% settles Jan 29
- Oct 29, 202618d ago DEF 14A Bearish 6/10 Entry $0.1206 Now $0.0820 +32.01% settles Jan 27
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $0.1347 Now $0.0820 −39.12% settles Jan 19
- Oct 19, 202628d ago Press Release Mixed 6/10 Entry $0.1410 Now $0.0820 −41.84% settles Jan 15
- Oct 19, 202628d ago 8-K Mixed 6/10 Entry $0.1406 Now $0.0820 −41.68% settles Jan 15
- Oct 15, 20264w ago 8-K Mixed 6/10 Entry $0.1428 Now $0.0820 −42.58% settles Jan 12
- Oct 15, 20264w ago Press Release Neutral 5/10 Entry $0.1428 Now $0.0820 −42.58% settles Jan 12
- Sep 30, 20266w ago 8-K Bearish 6/10 Entry $0.1490 Now $0.0820 +44.97% settles Dec 28
- Aug 28, 202611w ago Press Release Neutral 4/10 Entry $0.2249 Now $0.0820 −63.54% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers